KR20000005539A - Dhea복합요법 - Google Patents

Dhea복합요법

Info

Publication number
KR20000005539A
KR20000005539A KR1019980708339A KR19980708339A KR20000005539A KR 20000005539 A KR20000005539 A KR 20000005539A KR 1019980708339 A KR1019980708339 A KR 1019980708339A KR 19980708339 A KR19980708339 A KR 19980708339A KR 20000005539 A KR20000005539 A KR 20000005539A
Authority
KR
South Korea
Prior art keywords
interleukin
synthesis
compounds
receptor molecule
polyclonal
Prior art date
Application number
KR1019980708339A
Other languages
English (en)
Korean (ko)
Inventor
패트릭 티. 프렌더가스트
Original Assignee
패트릭 티. 프렌더가스트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 패트릭 티. 프렌더가스트 filed Critical 패트릭 티. 프렌더가스트
Publication of KR20000005539A publication Critical patent/KR20000005539A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
KR1019980708339A 1996-04-17 1997-04-17 Dhea복합요법 KR20000005539A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1569596P 1996-04-17 1996-04-17
US60/015,695 1996-04-17

Publications (1)

Publication Number Publication Date
KR20000005539A true KR20000005539A (ko) 2000-01-25

Family

ID=21773003

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019980708339A KR20000005539A (ko) 1996-04-17 1997-04-17 Dhea복합요법

Country Status (9)

Country Link
EP (1) EP0901375A1 (xx)
JP (1) JP2000508654A (xx)
KR (1) KR20000005539A (xx)
CN (1) CN1216470A (xx)
AU (1) AU734807B2 (xx)
CA (1) CA2251733A1 (xx)
IL (1) IL126623A0 (xx)
NO (1) NO984851L (xx)
WO (1) WO1997038695A1 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9915623A (pt) * 1998-11-24 2001-08-14 Hollis Eden Pharmaceuticals Uso de compostos de 17-cetoesteróides e derivados, metabolitos e precursores dos mesmos no tratamento de malária e no tratamento de tripanossomìase africana e americana
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
AU775614B2 (en) * 1998-11-24 2004-08-05 Harbor Biosciences, Inc. Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other togaviruses
AU1923500A (en) * 1998-11-27 2000-06-19 Hollis-Eden Pharmaceuticals, Inc. Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in treatment of toxoplasmosis and in the treatment of cryptosporidiosis
WO2014166501A2 (en) * 2013-04-10 2014-10-16 Skau Aps Use of immune suppressive peptides as adjuvants

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3815472A1 (de) * 1988-05-06 1989-11-16 Centre Regional De Transfusion Monoklonaler antikoerper und seine verwendung
IE882585L (en) * 1988-08-25 1990-02-25 Prendergast Patrick T Viral treatment system
US5231012A (en) * 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
IL106725A (en) * 1992-08-20 2000-12-06 Schering Plough Corp Pharmaceutical composition for treating inflammatory bowel disease comprising IL-10
US5449688A (en) * 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases

Also Published As

Publication number Publication date
IL126623A0 (en) 1999-08-17
JP2000508654A (ja) 2000-07-11
CN1216470A (zh) 1999-05-12
CA2251733A1 (en) 1997-10-23
AU2574197A (en) 1997-11-07
EP0901375A1 (en) 1999-03-17
NO984851L (no) 1998-12-17
AU734807B2 (en) 2001-06-21
NO984851D0 (no) 1998-10-16
WO1997038695A1 (en) 1997-10-23

Similar Documents

Publication Publication Date Title
Santoli et al. HLA-related control of spontaneous and antibody-dependent cell-mediated cytotoxic activity in humans
Gayraud et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides.
Teppler et al. Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection.
CZ182492A3 (en) Pharmaceutical preparation for treating t-cellular leukemia (lymphoma of adults)
AU2012228418A1 (en) Use of low dose IL-2 for treating autoimmune - related or inflammatory disorders
Gelfand et al. Partial purine nucleoside phosphorylase deficiency: Studies of lymphocyte function
Kalayjian et al. A phase I/II trial of intravenous L-2-oxothiazolidine-4-carboxylic acid (procysteine) in asymptomatic HIV-infected subjects
Bergamini et al. Macrophage colony-stimulating factor enhances the susceptibility of macrophages to infection by human immunodeficiency virus and reduces the activity of compounds that inhibit virus binding
Brockmeyer et al. Immunomodulatory properties of cimetidine in ARC patients
US5238689A (en) Use of ruthenium red as immunosuppressive agents
EP0916344A2 (en) Nef action inhibitor
KR20000005539A (ko) Dhea복합요법
BEELEN et al. Six weeks of continuous intravenous cyclosporine and short-course methotrexate as prophylaxis for acute graft-versus-host disease after allogeneic bone marrow transplantation
Kaneko et al. Role of tumour necrosis factor-alpha (TNF-α) in the induction of HIV-1 gp120-mediated CD4+ T cell anergy
Tenser et al. Immunoglobulin G immunosuppression of multiple sclerosis: suppression of all three major lymphocyte subsets
US5122372A (en) Process for treatment of allergies
WO1998047516A1 (en) Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
Hober et al. TNF-α production by U937 promonocytes is enhanced by factors released from HIV-infected T4 lymphocytes: TNF-α is one of the mediators causing lysis of HIV-infected T4 cells
ES2927550T3 (es) Remedio para pacientes con mielopatía asociada a HTLV-1
AU726909B2 (en) Therapeutic uses for an aminosterol compound
Stavinoha et al. Current therapy of chronic liver disease
CN112656801A (zh) 孕激素在治疗细胞因子释放综合征中的应用
Lin Improvement in Steroid and Immunosuppressive Drug Resistant Lupus nephritis by Intravenous Prostaglandin E1Therapy
Bartlett et al. Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with Walter Reed stage 2 human immunodeficiency virus infection: results of ACTG protocol 042
Uozumi et al. Serum dehydroepiandrosterone and DHEA‐sulfate in patients with adult T‐cell leukemia and human T‐lymphotropic virus type I carriers

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid